GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the drug.

Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication

Buy and hold GlaxoSmithKline Plc is far from the most radical or unique stock market call you'll see today, or any other day for that matter, nevertheless, European broker Berenberg says there's “deep value” for patient investors. Repeating a ‘buy' recommendation and upgrading its price target to £16.25 from £15.70, suggesting around 8% upside to the current price of £15.19.

GlaxoSmithKline investors set for deep value if they stay patient

GSK Next, the innovation arm of GlaxoSmithKlein, is launching a new mentorship and business development program. Called the Re/Wire Health Studio, the program will eventually select six startups who will win access to nine weeks of mentoring, business development expertise, and cash grants.

GSK and R/GA Ventures are launching a health studio for startups

Cardinal Health

Cincinnati Financial

Canadian Imperial Bank of Commerce

Cisco Systems

Genuine Parts

Huntington Bancshares

Illinois Tool Works

Leggett & Platt

Norfolk Southern

Realty Income Corp

Occidental Petroleum

Philip Morris

J. M. Smucker

Schlumberger

Scotts Miracle-Gro

T. Rowe Price Group

TotalEnergies SE

ViacomCBS

In July, we received $771.96 in dividend income! Our top dividend payment for the month was a HUGE special dividend payment from T. Rowe Price.

Dividend Income Summary: Bert's July 2021 Summary

GlaxoSmithKline (GSK) has been reinstated on the government-backed prompt payment code list after it failed to pay back invoices years ago. Previously, GSK was only paying 28 percent of its suppliers within 60 days in its consumer healthcare division and only 12 percent from the overall U.K. business.

GSK Sorts Invoice Issues, Returns To Prompt Payment Code

LTC Properties

LyondellBasell Industries

Altria

Prudential Financial

Walgreens

With the pandemic causing much uncertainty in the economy, these high-yielding dividend stocks to buy could offer some reassurances. The post 7 High-Yield Dividend Stocks to Get You Through Market Volatility appeared first on InvestorPlace.

7 High-Yield Dividend Stocks to Get You Through Market Volatility

The spin-off will provide increased focus and stronger GSK.

GlaxoSmithKline Is Relatively Undervalued And Spin-Off To Unlock Value

AstraZeneca

Under-fire boss of GlaxoSmithKline PLC, Emma Walmsley, has received support from an unlikely source: Pascal Soriot, the boss of rival pharma giant AstraZeneca PLC. In an interview with The Daily Mail, Soriot advised Walmsley to stick to her guns and implement her business plan.

AstraZeneca boss urges rival at GlaxoSmithKline to stick to her guns

AstraZeneca PLC boss urges rival at GlaxoSmithKline to stick to her guns

AbbVie

Gilead Sciences

Pfizer

The healthcare sector is chock-full of safe, sturdy income plays. But these five top-rated high-yield dividend stocks really stand out in the crowd.

5 High-Yield Dividend Stocks for Healthy Income

Any GlaxoSmithKline PLC recovery is unlikely to come through before 2022 and will be driven by new products, according to Swiss broker UBS. For the shares to be rerated, the pharma needs to show some earnings growth rather than just be seen as a value stock, says the broker.

GlaxoSmithKline improvement likely in 2022 according to UBS

GlaxoSmithKline Plc (NYSE: GSK) has submitted a marketing application to the FDA seeking approval for PRIORIX for use in active immunization against infection by measles, mumps, and rubella (MMR). GSK MMR vaccine is available in Europe since 1997.

GlaxoSmithKline Files US Application For Approval Of Its MMR Vaccine

The FDA approved GlaxoSmithKline Plc's (NYSE: GSK) Nucala (mepolizumab) for chronic rhinosinusitis with nasal polyps, making it the first IL-5 inhibitor to break into the indication. The approval comes as an add-on maintenance therapy for adults with inadequate response to nasal corticosteroids.

GlaxoSmithKline's Scores FDA Approval For First IL-5 Inhibitor In Nasal Polyps

LONDON--(BUSINESS WIRE)--GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps.

GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps

Amazon

Anheuser-Busch InBev

Great Elm Capital

Netflix

Tesla

USA Compression Partners

By, Bob Ciura Investors who are in retirement, or nearing retirement will have different needs than their younger counterparts still in the accumulation phase of their life. Retiring means losing the regular paycheck from work, and as a result, replacing that income is a key consideration.

Avoid These 7 Stocks in Retirement Like the Plague

Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.

Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track

GlaxoSmithKline's (GSK) CEO Emma Walmsley on Q2 2021 Results - Earnings Call Transcript

GlaxoSmithKline beat earnings expectations in the second quarter, as vaccine sales rebounded and the company's efforts in the fight against Covid began to pay off.

Glaxo Gets Vaccine Sales Boost and Covid-19 Efforts Start to Bear Fruit

GlaxoSmithKline Plc's (NYSE: GSK) turnover was £8.1 billion in Q2, up 6% Y/Y (actual exchange rate AER), 15% (constant exchange rate CER). Pharmaceuticals sales reached £4.2 billion, up 3% AER, 12% CER, driven by strong growth in New & Specialty products, favorable US RAR adjustments, and a prior year comparator impacted by destocking of COVID-19 related first quarter additional demand.

Vaccine Demand Boosts GlaxoSmithKline's Q2 Sales, Earnings; Maintains FY21 Guidance

Glaxo (GSK) beats earnings as well as revenues estimates in the second quarter of 2021. Stock up.

Glaxo (GSK) Beats Earnings and Revenues Estimates in Q2

Vir Biotechnology

Shares of Vir Biotechnology Inc. gained 1.9% in premarket trading on Wednesday after the company and GlaxoSmithKline said the European Commission purchased 220,00 doses of their investigational COVID-19 antibody treatment. The therapy is a single-dose monoclonal antibody that is being tested as a treatment to ward off severe disease in some high-risk COVID-19 patients.

Europe buys 220,000 doses of Vir, GSK's experimental COVID-19 treatment

GlaxoSmithKline PLC shares eased lower even though the pharma giant said results this year are likely towards the higher end of guidance.   Second-quarter sales to end June 2021 rose 6% to £8.1bn, though revenue growth was much stronger at 15% if the effect of currency movements were stripped out.

GlaxoSmithKline maintains guidance but Shingrix still sluggish

(Reuters) -GSK forecast a smaller drop in 2021 profit on Wednesday as the drugmaker beat second-quarter earnings expectations, buoyed by a pick up at its vaccines business as routine hospital visits recovered amid an of easing pandemic restrictions.

GSK sees smaller 2021 profit fall after Q2 beat

Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.

Glaxo (GSK) to Report Q2 Earnings: What's in the Cards?

Sanofi

EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NASDAQ: GSK), which started a 35,000-patient Phase 3 trial in May. The vaccine dubbed Vidprevtyn is based on a recombinant protein antigen developed by Sanofi and includes an immune-boosting adjuvant developed by GSK to boost its efficacy.

EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine

News for GlaxoSmithKline Stock (GSK)